Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2020, Vol. 25 ›› Issue (4): 393-400.doi: 10.12092/j.issn.1009-2501.2020.04.007

Previous Articles     Next Articles

Preparation of genistein combined polysaccharide liposomes and its inhibitory effects on prostate cancer

XU Shenghua1, GAO Zhuo2, WANG Jianfeng3   

  1. 1Intensive Care Unit, Dajiangdong District of the First People's Hospital of Hangzhou, Hangzhou 311225, Zhejiang, China; 2Department of Pathology, Dajiangdong District of the First People's Hospital of Hangzhou, Hangzhou 311225, Zhejiang, China; 3Department of Urinary Surgery, Dajiangdong District of the First People's Hospital of Hangzhou, Hangzhou 311225, Zhejiang, China
  • Received:2019-08-09 Revised:2020-03-30 Online:2020-04-26 Published:2020-05-12

Abstract: AIM: To prepare genistein combined polysaccharide (GCP) liposomes and to evaluate the potential value of GCP liposomes for the treatment of prostate cancer by in vivo and in vitro experiments, and ultimately to promote the application of nanotechnology in prostate cancer chemotherapy. METHODS: GCP liposomes were prepared by ethanol injection. The anti-tumor effect of GCP liposomes was verified in vitro and in vivo by cell proliferation assay and cell cycle analysis, as well as establishing a tumor model of prostate cancer.RESULTS:GCP liposomes enhanced the inhibitory effect of GCP on androgen-sensitive LNCaP cell proliferation and the apoptosis of androgen-sensitive LNCaP cells induced by GCP. Also, GCP liposomes improved the inhibitory effect of GCP on tumor growth in tumor-bearing mice. CONCLUSION: GCP liposomes have better anti-tumor effect on androgen-sensitive human prostate cancer cells than GCP.

Key words: genistein combined polysaccharide, liposomes, prostate cancer

CLC Number: